Zika vaccine race spurred by crisis and profit potential
EghtesadOnline: The race to find protection against the  Zika  virus is fueled by something often missing from tropical disease research: the potential for big profit. The prospect of a blockbuster vaccine against a mosquito-borne virus has accelerated the pace of development and attracted the interest of big drugmakers, including Sanofi SA, GlaxoSmithKline Plc and Takeda Pharmaceuticals.
                                                    
                                    
                                    |
                                
                                Publish Date:04/October/2016 | 08:10